Ajanta Pharma Limited
Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai 400 093, India

T +91 22 6060 9000
E legal.info@ajantapharma.com
W www.ajantapharma.com

Great Place To Work. Certified FEB 2026-FEB 2027 INDIA

2nd July 2026

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Scrip Code: AJANTPHARM EQ

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: AJANTPHARM 532331

Sub.: Update on US FDA inspection at Paithan manufacturing facility

Dear Sir/Madam,

We are pleased to inform you that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Paithan, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI).

The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from 13 April 2026 to 21 April 2026. The Company had earlier intimated the stock exchanges regarding the inspection on 22 April 2026.

This is for your information and records.

Thanking you,

Yours faithfully,

GAURANG CHINUBHAI SHAH
Digitally signed by GAURANG CHINUBHAI SHAH
Date: 2026.07.02 13:47:49 +05'30'

Gaurang Shah
Sr. VP – Legal & Company Secretary